INTRODUCTION
A ribozyme is an RNA enzyme and can cleave mRNAs specifically. This ability of ribozymes leads to apply a gene therapy targeting oncogenes and genes derived from viruses. In the case of application of ribozymes targeting oncogenes for a cancer gene therapy, however, it is possible that these ribozymes affect in normal cells because these genes function in normal cells. Then, these ribozymes cause the cytotoxicity in these cells.
The maxizyme, developed by our group, consists of two minizymes, and can cleave two distinct target sites (1, 2). The maxizyme also has an allosteric function that it can form an active conformation only when it specifically binds two target sites in these mRNAs (3, 4) . Therefore, we tried to construct the allosteric fraws-maxizyme that function only in cancer cells.
In this study, we focused two distinct oncogenes, hst-1 and cyclin Dl, for a breast cancer gene therapy.
These oncogenes are overexpressed in breast cancer cells and are also necessary for a growth factor-dependent signal transduction and a cell cycle in normal cells (5) .
We constructed the allosteric frans-maxizyme, which can function only when it specifically recognizes two target sites at the same time.
The maxizyme could be expected to cleave hst-1 and cyclin Dl only in breast cancer cells.
RESULTS AND DISCUSSION
At first, we designed a frans-maxizyme that can form an active conformation only when it binds these two mRNAs using the mulfold program that can calculate a secondary structure of RNA as shown in figure 1 . Figure 1 ) and MzR (maxizyme right; Figure 1 ). This maxizyme is transcribed by RNA polymerare III and it could be expected to form dimmers significantly in cells (6, 7). In addition, it can be transported from the nucleus to the cytoplasm, thereby ensuring the colocalization of the frans-maxizyme with its target mRNA.
To confirm whether the frans-maxizyme show an allosteric effect, we performed in vitro cleavage aasay.
In this assay, the maxizyme was transcribed by T7
polymerase in vitro and substrates of the transmaxizyme, namely hst-l-S and cyclin Dl-S, were synthesized by DNA synthesizer. Then, we confirmed that the maxizyme cleaved these substrates efficiently and it hardly worked in the presence of only each substrate (data not shown).
These results indicated clearly that our maxizyme formed the active conformation and cleaved efficiently only when it binds two distinct substrates in vitro.
Moreover, to examine the efficacy of the maxizyme in vivo, the maxizyme expressing vector was introduced into MCF-7 cells derived from a tumor breast tissue and into normal breast cell lines. We are now examining the effect of the frans-maxizyme in both cell lines. The maxizyme could be expected to work in MCF-7 cells
and not to work in normal cells.
